Commercial StrategyInsmed's salesforce capacity is prepared to contact every single pulmonologist in the US in both academic and community settings.
Drug ApprovalThere is a 90% confidence in FDA approval for brensocatib, which could lead to a new trajectory for INSM.
Market PotentialOnce daily dosing offers a clear edge for TPIP over peers, potentially capturing meaningful market share.
Sales PerformanceArikayce continues to grow, with 4Q24 as the highest single quarter sales to date.